is this the bif deal, page-17

PHYLOGICA AND PFIZER COMPLETE FIRST STAGE OF PEPTIDE VACCINE
COLLABORATION
PERTH, AUSTRALIA: December 12, 2011 – Phylogica Ltd (ASX: PYC, XETRA:
PH7), a public Australian peptide drug discovery company, announced today the
successful completion of the first stage of its collaboration with Pfizer to discover
novel peptide-based vaccines. Under the terms of the agreement, Phylogica will
receive an undisclosed milestone payment.
Phylogica and Pfizer entered into the collaboration in December 2010. Under the
collaboration, Phylogica has successfully identified several peptides from its
Phylomer? libraries that will be further evaluated for their potential as candidate
antigens for a vaccine against an undisclosed disease target.
Commenting on the news, Phylogica’s CEO, Dr Paul Watt, said: “We are very
pleased to report the successful completion of the initial phase of our collaboration
with Pfizer. We have identified multiple novel Phylomers that meet the criteria
required for further evaluation by Pfizer. This provides additional support for the
potential value of our Phylomer? libraries as a source of novel peptide drug
candidates.”